Impella

Type: Product
Name: Impella
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Transradial Unprotected Left Main PCI With Use of the Impella

Disclosure: Orlando Marrero reports no conflicts of interest regarding the content herein. Dr. Zaheed Tai reports the following: Terumo (proctor for transradial course), Spectranetics (proctor for laser course, speaker, advisory board), Medicines Company ... [Published Cath Lab Digest - Oct 15 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Arizona man's life saved using tiny heart pump

PHOENIX - A man who flat lined three times after suffering a heart attack reunited Thursday with the medical team that saved his life using the world's smallest heart pump.Borys Meleshko, a Cave Creek resident, had suffered a heart attack in June and ... [Published ABC15.com - Oct 10 2014]
First reported Oct 08 2014 - Updated Oct 09 2014 - 1 reports

Impella RP Clinical Trial Results Released

The page you requested does not exist. For your convenience, a search was performed using the query article impella rp clinical trial results released .Search results Article - mshoup - October 8, 2014 - 0 comments - 0 attachments - 1 domainImpella RP ... [Published Diagnostic & Invasive Cardiology - Oct 08 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

ABIOMED : Controllers Engineering Service Sought by Veterans Affairs

By Targeted News ServiceWASHINGTON , Sept. 27 -- The U.S. Veterans Affairs Department's Long Beach Healthcare System , Long Beach, California , has issued a pre-solicitation notice (VA26214Q1575) for engineering service for two Abiomed Impella automated ... [Published 4 Traders - Sep 30 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Trade Press Release: CAE Healthcare delivers simulation-based training solution to Abiomed for its Impella heart pump

By a News Reporter-Staff News Editor at Cardiovascular Week -- CAE Healthcare announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2014, the world's largest educational meeting specializing in interventional cardiovascular medicine, that it ... [Published 4 Traders - Sep 24 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

US Federal Business Opportunity: Department of Veterans Affairs: J--Service Contract for Government Owned ABIOMED Imepella Controllers

Agency: Department of Veterans AffairsOffice: Long Beach VANLO Location: Department of Veterans AffairsDate you need to respond by: 29-September-2015Solicitation Number: VA26214Q1575 Naics code: 334510 Computer and Electronic Product ManufacturingDe ... [Published ITbriefing - Sep 24 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Abiomed appoints director of investor relations

Abiomed Inc., a provider of heart support technologies, has appointed Ingrid Goldberg as director of investor relations. "We are extremely pleased to have Ingrid on board during a pivotal time of growth and opportunity for the Company," said Michael R. ... [Published Individual.com - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

VADs Gaining Popularity, But Artificial Hearts Remain the Ideal, Says GlobalData Analyst

— Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said:“Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly in size, design and power usage, but many problems related ... [Published Diagnostic & Invasive Cardiology - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Update: Abiomed Announced Clinical Trial Results For Impella RP

Summary Abiomed announced RECOVER RIGHT clinical trial results for Impella RP earlier this week. In my original article I mentioned that Abiomed started enrolling patients for the RECOVER RIGHT clinical trial. The result remained promising for the ... [Published Seeking Alpha - Sep 19 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 2 reports

Clinical Trial Results For Impella RP Right Ventricular Heart Failure Trial "Recover Right" Released At TCT 2014

Abiomed Inc. (Nasdaq: ABMD[1]), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Percutaneous) System. The ... [Published DailyMe.Com - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 16 2014 - 2 reports

TSX Ends Lower On Global Growth Worries -- Canadian Commentary

Canadian stocks ended lower Monday, tracking declining global stocks with investor concerns over global economic growth after some disappointing economic data from China and the uncertainty related to the outlook for U.S. interest rates.The decline was ... [Published RTTNews.com - Sep 15 2014]
First reported Sep 13 2014 - Updated Sep 13 2014 - 3 reports

CAE Healthcare Delivers Simulation-based Training Solution To Abiomed

CAE Healthcare, a unit of Canadian aviation-training and simulation products provider CAE, Inc. (CAE: Quote,CAE.TO: Quote) Saturday said it is delivering a simulation-based solution to Abiomed, Inc. (ABMD: Quote), a provider of breakthrough heart support ... [Published RTTNews.com - Sep 13 2014]

Quotes

..." said Jonathan Ross Goodman , President and CEO of Knight. "We intend to commit up to $130 million Canadian in total to this strategy with our long term goal of creating Canada's largest innovative pharmaceutical pipeline. This leaves at a minimum $105 million Canadian from which we will continue to aggressively execute on our proven strategy of fueling low risk, sustained growth through (1) in-licensing late-stage pharmaceutical products for the Canadian market, (2) acquisition of products or companies with existing pharmaceutical revenues and (3) secured lending to innovative pharmaceutical companies."
...technologies to supplement our educational programs," said Michael R Minogue , Chairman President and ChiefChief Executive Officer, of Abiomed . "Our partnership with CAE demonstrates our responsibility to providing high quality training tools for our customers."
...Ingrid on board during a pivotal time of growth and opportunity for the Company," said Michael R Minogue, Chairman, President and CEO of Abiomed. "With her background and experience, Ingrid is well-positioned to maintain effective relationships with investors to help us continue growing shareholder value."
...Michael R Minogue, Abiomed's Chairman, President and CEO, said, "The Impella RP is the first percutaneous, single vascular access pump designed for right heart support. The pump is designed to be used concurrently with other left ventricle pumps in the Impella platform, which in the future may offer physicians the option of percutaneous biventricular support for acute patients."

More Content

All (29) | News (21) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Transradial Unprotected Left Main PCI With Use ... [Published Cath Lab Digest - Oct 15 2014]
Arizona man's life saved using tiny heart pump [Published ABC15.com - Oct 10 2014]
Impella RP Clinical Trial Results Released [Published Diagnostic & Invasive Cardiology - Oct 08 2014]
Forbion Capital Partners Announces First Close ... [Published BioSpace - Oct 03 2014]
Knight Therapeutics : Expands Its Innovative Ph... [Published 4 Traders - Oct 02 2014]
ABIOMED : Controllers Engineering Service Sough... [Published 4 Traders - Sep 30 2014]
Trade Press Release: CAE Healthcare delivers si... [Published 4 Traders - Sep 24 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Sep 24 2014]
Abiomed appoints director of investor relations [Published Individual.com - Sep 22 2014]
VADs Gaining Popularity, But Artificial Hearts ... [Published Diagnostic & Invasive Cardiology - Sep 22 2014]
Update: Abiomed Announced Clinical Trial Result... [Published Seeking Alpha - Sep 19 2014]
Abiomed Appoints Ingrid Goldberg as Director of... [Published Fat Pitch Financials - Sep 18 2014]
Clinical Trial Results For Impella RP Right Ven... [Published DailyMe.Com - Sep 17 2014]
Abiomed Inc. Announces Clinical Trial Results F... [Published BioMedReports - Sep 17 2014]
Clinical Trial Results for Impella RP Right Ven... [Published GlobeNewswire: Music News - Sep 16 2014]
Clinical Trial Results for Impella RP Right Ven... [Published SPi World News - Sep 16 2014]
TSX Ends Lower On Global Growth Worries -- Cana... [Published RTTNews.com - Sep 15 2014]
Canadian Stocks Drift Lower On Global Economic ... [Published RTTNews.com - Sep 15 2014]
CAE Healthcare Delivers Simulation-based Traini... [Published RTTNews.com - Sep 13 2014]
Trade Press Release: CAE Healthcare delivers si... [Published MarketWired - Sep 13 2014]
Trade Press Release: CAE Healthcare delivers si... [Published Marketwire - Breaking News Releases - Sep 13 2014]
Ventricular Assist Devices Gaining Popularity, ... [Published Medical Design Technology - Sep 11 2014]
Data From RECOVER RIGHT Impella RP Trial to be ... [Published GlobeNewswire: Acquisitions News - Sep 10 2014]
Forbion Capital to sell Santaris Pharma to Roch... [Published PE Hub Blog - Aug 05 2014]
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
Forbion Announces Closing of Public Offering of... [Published BioPortfolio - Feb 20 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Trade Press Release: CAE Healthcare delivers si... [Published Marketwire - Breaking News Releases - Sep 13 2014]
CAE VIMEDIX Impella simulator allows physicians to practice placement of device in the left ventricle using fluoroscopic and ultrasound guidance ...
Forbion Capital to sell Santaris Pharma to Roch... [Published PE Hub Blog - Aug 05 2014]
Forbion Capital Partners has sold biopharmaceutical company Santaris Pharma A/S for $450 million to Roche . The deal is structured with an upfront cash payment of $250 million and additional contingent payments of up to $200 million based on achievement ...
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners ‘ portfolio company. PRESS RELEASE Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare ...
1

Press Releases

sort by: Date | Relevance
Clinical Trial Results for Impella RP Right Ven... [Published GlobeNewswire: Music News - Sep 16 2014]
Data From RECOVER RIGHT Impella RP Trial to be ... [Published GlobeNewswire: Acquisitions News - Sep 10 2014]
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.